*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
LungLife is a developer of clinical diagnostic solutions for lung cancer enhanced by artificial intelligence ("AI"). Lung cancer is one of the most lethal cancers, accounting for nearly a quarter of all cancer-related deaths in the US, and its global incidence has increased by 37 per cent. from 2007-2017. The Company's diagnostic solutions are designed to make significant improvements in the early detection of lung cancer.
Registrars:
Key Personnel
CEO:
Paul Carmelo Pagano
Non-Executive Director:
Sara Barrington
Non-Executive Chairman:
Gordon Roy Davis
Senior Independent Non-Executive Director:
Andrew Norman Boteler
Chief Finance Officer:
David Mark Anderson
Contact Details
Address:
850 New Burton Road, Suite 201, Dover, Delaware, USA